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Abstract ErbB2 functions as a shared signal transducing
component for other ErbB receptor family members. Two of
these receptors, ErbB3 and ErbB4, bind the heregulin (HRG) or
neuregulin family of polypeptide growth factors. Cells expressing
ErbB3 alone display a single class of low affinity HRG binding
sites, whereas both high and low affinity binding sites can be
measured on cells that co-express both ErbB3 and ErbB2. To
assess the interaction of the extracellular domains of ErbB
receptors, a series of soluble homodimeric and heterodimeric IgG
fusion proteins were constructed. Heregulin binding analysis
revealed that a heterodimer composed of either ErbB3 or ErbB4
with ErbB2 is sufficient for the formation of a high affinity
binding state. In contrast, heterodimeric ErbB3/4-IgG, as well as
homodimeric ErbB3-IgG or ErbB4-IgG, contained only low
affinity HRG binding sites. Further evidence for the unique
specificity of ErbB2 in generating this high affinity binding site
was determined by inhibiting HRG binding with an ErbB2
monoclonal antibody.
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1. Introduction
Neuregulins are a family of related gene products that bind
directly to ErbB3 or ErbB4. Transactivation of ErbB2 as a
result of ligand binding to other ErbB receptor family mem-
bers (EGFR, ErbB3 and ErbB4) is dependent upon cellular
context and relative receptor levels but is nonetheless a com-
mon and signi¢cant occurrence (for a review see [1]). In these
receptor complexes, ErbB2 contributes its potent tyrosine kin-
ase domain and additional tyrosine residues which upon phos-
phorylation provide docking sites for SH2 or PTB domain
proteins resulting in activation and ampli¢cation of multiple
signal transduction pathways [2,3]. Interaction of ErbB2 with
ErbB3 is of particular importance since ErbB3 lacks intrinsic
tyrosine kinase activity [4]. Neuregulin activation of ErbB2 is
physiologically relevant at neural-muscular junctions [5^7]
and at neural-Schwann cell junctions [8^10]. In cell culture
experiments using human tumor cell lines, several reports
have shown that ablating the interaction of ErbB2 with either
ErbB3 or ErbB4 diminishes downstream signaling as well as
subsequent biological responses such as growth [2,11,12].
Although ErbB2 is not activated directly by any known
ErbB ligand, the necessity of ErbB2 as a critical signal trans-
ducing element within the ErbB system is further substanti-
ated by the remarkable similarity of the phenotypes of mice
with their ErbB2 [13], ErbB4 [14] or neuregulin [15] genes
independently disrupted. Mice that are homozygous for these
mutations die at around embryonic day 10.5, and in each case
death is due to the lack of ventricular trabeculation in the
heart.
Previously, we have shown co-expression of ErbB2 with
ErbB3 leads to the formation of a high a⁄nity HRG binding
site in COS cells [16]. To further assess the molecular nature
of the interactions among these receptors, we sought an ex-
perimental system to study the receptors in a non-cellular
context. In particular, we questioned whether the extracellular
domains (ECDs) of ErbB2 with ErbB3 or ErbB4 were su⁄-
cient to mediate receptor interactions and to form a high
a⁄nity binding site for HRG. Since earlier physical-chemical
studies have not shown association of the ECDs of ErbB2 and
ErbB3 [17], we employed a strategy to generate a series of
chimeric proteins in which the ECDs of the ErbB receptor
proteins were fused to the hinge and Fc regions of human
IgG1 heavy chain [18]. Dimerization of these fusion proteins
occurs through the formation of two interchain disul¢de
bonds that are formed between the two hinge regions contrib-
uted by the IgG fusion partners. Homodimeric and heterodi-
meric [19,20] ErbB-IgG fusion proteins were constructed uti-
lizing all combinations of ErbB2, ErbB3 and ErbB4 ECDs.
Here, we report that measurement of HRG binding constants
for soluble ErbB receptors are similar to those determined for
intact receptors when expressed in mammalian cells.
2. Materials and methods
2.1. Expression plasmid construction
A unique MluI site was engineered into a plasmid expressing human
IgG heavy chain (pDR2, a gift from J. Ridgway and P. Carter, Gen-
entech, Inc.) at the region encoding the hinge domain of the immu-
noglobulin. MluI sites were also engineered into a set of ErbB expres-
sion plasmids at the region encoding the ECD/TM junctions of these
receptors. All mutagenesis were done using the Kunkel method [21].
The MluI sites were utilized to make the appropriate ErbB-IgG fusion
constructs. The fusion junctions (using the residue numbering system
described in Plowman et al. [22] for the ErbB extracellular domains)
of the various ErbB-IgG chimeras were: for ErbB2, E646ErbB2-(TR)-
DKTH224VH ; for ErbB3, L617ErbB3-(TR)-DKTH224VH ; for ErbB4,
G640ErbB4-(TR)-DKTH224VH. The conserved TR sequence is derived
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from the MluI site. The ¢nal expression constructs were in a pRK-
type plasmid backbone wherein eukaryotic expression is driven by a
CMV promoter [23].
2.2. Protein expression
To obtain protein for in vitro experiments, adherent HEK-293 cells
were transfected with the appropriate expression plasmids using
standard calcium phosphate methods [23]. Serum-containing medium
was replaced with serum-free medium 15 h post transfection and the
transfected cells were incubated for 5^7 days. The resulting condi-
tioned medium was harvested and passed through protein A columns
(1 ml Pharmacia HiTrap). Puri¢ed IgG fusions were eluted with 0.1 M
citric acid (pH 4.2) into tubes containing 1 M Tris pH 9.0. The eluted
proteins were subsequently dialyzed against PBS and concentrated
using Centri-prep-30 ¢lters (Amicon). Glycerol was added to a ¢nal
concentration of 50% and the material stored at 320‡C. Protein con-
centrations were determined by a Fc-ELISA or quantitative amino
acid analysis.
2.3. Immunoprecipitation and Western blots
Immunoprecipitations were performed with monoclonal antibodies
to the extracellular domain of ErbB2 or ErbB4. For analysis of the
ErbB4-containing heterodimers, each ErbB-IgG protein (0.2 Wg) was
incubated overnight at 4‡C with biotinylated antibody (0.6 Wg) to
ErbB4 (Genentech, MAb 1459) in phosphate bu¡ered saline contain-
ing 0.1% CHAPS and 0.1% Tween-20 with streptavidin-agarose beads
(Pierce cat. #53146), which had been previously absorbed with human
IgG. For the analysis of the ErbB2/3-IgG heterodimers, the anti-
ErbB2 monoclonal antibody, 2C4 [24], was directly coupled to an
a⁄nity matrix (A⁄-Prep 10, Bio-Rad) at approximately 2 mg/ml of
support. Immunoprecipitations were performed as described above
using 250 Wl of 2C4 beads. After thorough washing with bu¡er, pro-
teins were eluted from the a⁄nity matrices by boiling in 60 Wl of SDS
sample bu¡er containing 25 mM DTT for 5 min. Samples (30 Wl/lane)
were electrophoresed on a 4^20% SDS polyacrylamide gel (Novex)
and then transferred to nitrocellulose. Blots were blocked with 5%
BSA or 5% non-fat milk in Tris-HCl bu¡er, pH 7.2 with 0.15 M
NaCl and 0.1% Tween-20 and probed with a rabbit polyclonal anti-
ErbB2 (Genentech) or anti-ErbB3 antibody (Transduction Labs, cat.
#E38530) at a dilution of 1/10,000 and 1/250, respectively, and then
with anti-rabbit horseradish peroxidase-conjugated secondary anti-
body (Biosource, cat. #ALI3404). Bands were visualized using en-
hanced chemiluminescence with reagents from Amersham or Pierce.
2.4. Binding assays
The EGF-like domain of HRGL1, amino acids 177^244, was ex-
pressed in bacteria and used in all binding assays. Radioiodination of
the peptide was done as previously described [16]. Binding assays were
performed in Nunc break-apart immuno-module plates. Plate wells
were coated overnight with 100 Wl of 5 Wg/ml goat anti-human Ab
(Boehringer Mannheim) in 50 mM carbonate bu¡er (pH 9.6) at 4‡C.
Wells were rinsed twice with 200 Wl of WB (wash bu¡er: PBS/0.05%
Tween-20) followed by incubation with 100 Wl PBS/1% BSA (15^30
min at room temperature). ErbB3/4 heterodimer and the ErbB3 and
ErbB4 homodimers were coated at 30 ng/well, whereas the ErbB2/3
and ErbB2/4 heterodimers were coated at 1 ng/well. ErbB-IgG fusions
(100 Wl) in PBS/1% BSA were added to each well and incubated at
room temperature for 1 h with vigorous mixing. Following three
rinses with WB, 125I-HRG plus varying concentrations of cold com-
petitor were added to wells and incubated at room temperature for 2^
3 h with vigorous side-to-side rotation. Wells were then quickly rinsed
three times with WB, drained, and individual wells broken apart and
counted using a 100-Series Iso-Data Q-counter. Scatchard analysis was
performed using a modi¢ed Ligand program [25]. Each incubation
condition was performed in triplicate and experiments were repeated
on average 2^3 times.
3. Results
We made a series of plasmid constructs that permitted the
eukaryotic expression of the ECDs of ErbB receptors fused to
the constant domains of human IgG. These receptor-IgG con-
structs exist in solution as disul¢de-linked dimers. Homodi-
meric IgG receptors for ErbB2, ErbB3 and ErbB4 were indi-
vidually expressed in HEK-293 cells and the resulting secreted
receptor fusion proteins were puri¢ed by a⁄nity chromatog-
raphy on protein A. Previously, Chen et al. [26] and Tzahar et
al. [27] have reported similar constructions of homodimeric
ErbB3- and ErbB4-IgG fusion proteins. Heterodimeric ver-
sions of the receptor-IgG constructs were generated by trans-
fecting two expression plasmids encoding di¡erent receptors
into the same cell. The resulting secreted forms of the recep-
tor-IgGs are mixtures of two types of homodimers and the
expected heterodimer. Three di¡erent co-transfections were
performed to generate the following ErbB mixtures: ErbB2/
3-IgG, ErbB2/4-IgG and ErbB3/4-IgG. The presence of het-
erodimers in these mixtures was veri¢ed by immunoprecipita-
tion with speci¢c ErbB monoclonal antibodies and Western
blot analysis. As shown in Fig. 1, the presence ErbB2/3-IgG
heterodimer is veri¢ed when anti-ErbB2 immunoprecipitates
are probed in a Western blot using antibodies speci¢c for
ErbB3. Similar analysis was performed with the ErbB2/4-
IgG and the ErbB3/4-IgG heterodimers. No immunoblot sig-
nals were observed when homodimeric receptor fusion pro-
teins were used for immunoprecipitation.
Binding analysis of these receptor fusion proteins was per-
formed by immobilizing the receptor fusion proteins in micro-
titer plates coated with an anti-human monoclonal antibody.
As shown in Fig. 2A, a high a⁄nity HRG binding site could
be detected with the ErbB2-containing heterodimers but not
the ErbB3/4 heterodimer. Scatchard plots of these data were
curvilinear for the ErbB2-containing heterodimer mixtures
(Fig. 2B,C) suggesting two distinct types of binding sites
FEBS 20500 13-7-98
Fig. 1. Analysis of ErbB-IgG fusion proteins. Monoclonal antibod-
ies to ErbB2 or ErbB4 were used for immunoprecipitation (IP) as
described in Section 2. Immune complexes were subjected to SDS
gel electrophoresis and then transferred to nitrocellulose. Blots were
then probed with anti-ErbB2 or anti-ErbB3 antibody (Transduction
Labs).
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[25]. A Kd of 0.013 nM was measured for the high a⁄nity
ErbB2/3-IgG binding site, whereas a low a⁄nity binding site
was estimated to be 6.5 nM. In this case, cotransfection gen-
erates a mixture of the desired ErbB2/3-IgG heterodimer, as
well as the ErbB2-IgG and ErbB3-IgG homodimers. Since the
ErbB2-IgG is inactive, the low a⁄nity binding site presumably
re£ects the ErbB3-IgG homodimer. Regardless, the calcula-
tion for the a⁄nity constants is independent of receptor con-
centration. The high a⁄nity binding constant is in agreement
with the values measured when ErbB3 is expressed in cells
containing high levels of ErbB2 [28] or when high a⁄nity
HRG binding sites are determined from a two-site ¢t of bind-
ing data in high ErbB3 backgrounds [16]. Interestingly,
ErbB2/4-IgG (Fig. 2C) also exhibited a similar a⁄nity shift
when compared to the ErbB4-IgG homodimer. The measured
a⁄nity constant for the ErbB2/4-IgG was 0.025 nM. Again
using a two-site ¢t, a low a⁄nity binding site Kd of 4.3 nM
could also be estimated. As observed with the ErbB2/3-IgG,
this value is in close agreement with the Kd measured for the
ErbB4-IgG homodimer. Although ErbB2 transactivation of
ErbB4 has been reported previously [12,29,30], this is the ¢rst
time when ErbB2 has been shown to modulate the binding
a⁄nity of ErbB4 for HRG. The ErbB3/ErbB4-IgG mixture
(Fig. 2D) displayed a single low a⁄nity binding site with a Kd
of 6 nM, which was comparable to that observed for the
ErbB3-IgG and ErbB4-IgG homodimers. Thus, the formation
of a high a⁄nity ligand binding site correlated with the pres-
ence of the ErbB2 ECD with an ECD of ErbB3 or ErbB4,
suggesting ErbB2 was required for the formation of a high
a⁄nity site. A summary of binding constants for the ErbB-
IgG fusion proteins is shown in Table 1. The values for the
ErbB3-IgG and ErbB4-IgG are in agreement with those re-
ported by Tzahar et al. [27] using surface plasmon resonance.
In contrast however, using our assay conditions, we were un-
able to detect any binding with the ErbB2-IgG construct. The
high a⁄nity binding sites that were formed for the heterodi-
meric ErbB2/3-IgG or ErbB2/4-IgG protein were 200^700-fold
higher than for the corresponding homodimeric species.
To further evaluate the contribution of ErbB2 to the for-
mation of the high a⁄nity binding site, we examined the e¡ect
of an anti-ErbB2 ECD antibody to inhibit high a⁄nity bind-
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Fig. 2. Binding analysis of 125I-HRGL1 to heterodimeric ErbB-IgG fusion proteins. Binding assays were performed in a 96-well plate format as
described in Section 2. ErbB-IgG fusion proteins were immobilized using goat anti-human Ab (Boehringer Mannheim). 125I-HRG plus varying
concentrations of cold competitor were added to wells and incubated at room temperature for 2^3 h with vigorous mixing. Wells were then
quickly rinsed three times with WB, drained, and individual wells broken apart and counted. Scatchard analysis was performed using a modi-
¢ed Ligand program [25]. A: Displacement of 125I-HRGL1 to ErbB2/4-IgG, ErbB3/4-IgG, and ErbB2/3-IgG. B: Scatchard analysis of HRG
binding to ErbB2/3-IgG. C: ErbB2/4-IgG. D: ErbB3/4-IgG.
Table 1
Summary of binding constants for ErbB-IgG fusion proteins
ErbB-IgG construct Kd (nM)
low a⁄nity site high a⁄nity site
ErbB2 NMBa ^
ErbB3 9.1 þ 2.9 NDb
ErbB4 5.0 þ 0.8 ND
ErbB2/3 6.5 þ 4.8 0.013 þ 0.003
ErbB2/4 4.3 þ 2.1 0.025 þ 0.006
ErbB3/4 6.0 þ 0.7 ND
aNo measurable binding.
bSecond site not detected.
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ing to the ErbB-IgGs. Binding reactions were conducted in the
presence of a monoclonal antibody, 2C4, which is speci¢c for
the ErbB2 ECD [11]. As shown in Fig. 3A, the addition of
2C4 had a marked inhibitory e¡ect on HRG binding for the
ErbB2/ErbB3-IgG heterodimer but not for the corresponding
ErbB3-IgG homodimer. Similarly, the anti-ErbB2 monoclonal
antibody also blocked HRG binding to the ErbB2/ErbB4-IgG
heterodimer (Fig. 3B) but not to the corresponding ErbB4-
IgG homodimer.
4. Discussion
This report is the ¢rst example where a⁄nity modulation
due to ErbB-receptor heterodimerization has been demon-
strated in a cell-free system. These data con¢rm and extend
the results recently reported by Tzahar et al. [27] who found
that ErbB3-ErbB2 heterodimerization is strictly dependent on
a speci¢c type of membrane anchorage. We did not, however,
observe an increase in binding a⁄nity when we mixed ErbB2-
IgG homodimers with homodimers of ErbB3-IgG or ErbB4-
IgG (data not shown). These data are in agreement with a
biophysical study using the ECDs of ErbB2 and ErbB3 that
also failed to show receptor association [17]. We conclude that
the Fc component of the IgG fusion partner functions to
facilitate heterodimerization in a manner similar to the trans-
membrane regions that are normally present with the intact
receptors. Additionally, the £exibility of the hinge region may
allow the receptors to be oriented to one another such that the
high a⁄nity site is reconstituted [18].
Although ErbB2 transactivation of ErbB4 has been re-
ported previously [29], this is the ¢rst time that ErbB2 has
been shown to modulate the binding a⁄nity of ErbB4 for
HRG. Unlike ErbB3, ErbB4 is a fully active tyrosine kinase
and ectopically expressed ErbB4 signals in the absence of
ErbB2 or other related receptors [12,30]. Paradoxically, in
normal biological systems, ErbB4 appears to require concom-
itant ErbB2 expression. For example, in the developing heart,
both ErbB2 and ErbB4 are essential for the initiation of car-
diac trabeculation [13,14]. ErbB4 has also been shown to play
an important role in the central nervous system with regard to
the communication between axons and glia. In particular, it
has recently been demonstrated that neuregulin promotes the
survival of oligodendrocyte-type II astrocyte (O2A) progeni-
tor cells [31]. Interestingly, greater than half maximum surviv-
al of O2A cells occurs at neuregulin concentrations of V50
pM. These observations suggest that ErbB4 alone is not solely
contributing to this biological response since it occurs at lig-
and concentrations that are far below the reported Kd for
ErbB4 [32]. Moreover, it has been recently reported that
O2A cells express ErbB4 and ErbB2 but no ErbB3 and
both ErbB4 and ErbB2 are activated upon neuregulin treat-
ment [33]. Our current ¢nding that ErbB2 can modulate the
heregulin binding activity of ErbB4 provides a biochemical
basis for the neuregulin survival response observed with
O2A progenitor cells.
The rami¢cations of ErbB2 modulation of other ErbB re-
ceptors are of particular interest in epithelial-derived human
cancers [34,35] where ErbB2 is known to be overexpressed. In
these neoplasms ErbB2 protein levels are frequently 5^100
times greater than that found in the adjacent, non-malignant
tumor tissue. Since di¡usion within the plasma membrane
occurs in only two dimensions, the e¡ective increase in recep-
tor concentration is much higher. At the molecular level, the
implications of ErbB2 overexpression might result in receptor
activation by at least two di¡erent mechanisms. First, high
levels of ErbB2 could lead to ligand-independent homo-oligo-
merization resulting in constitutive activation and aberrant
signaling. Second, since ErbB2 functions to augment ErbB
signaling [30,36] and is the preferred hetero-oligomerization
partner [2,37], overexpression of ErbB2 in tumor cells may
drive the formation of ligand-independent heterooligomers
that are primed to receive and respond to exogenous soluble
growth factors [38]. In agreement with this hypothesis, Zhang
et al. have recently reported that NIH 3T3 transformation by
ErbB3 or ErbB4 requires the presence of ErbB1 or ErbB2
[39]. Our present ¢ndings demonstrate that modulation of
ErbB3 and ErbB4 is a speci¢c characteristic of the ECD of
ErbB2. These results extend the existing notion that down
modulation of ErbB2 expression or function may be bene¢cial
in inhibiting the growth of human malignancies where acti-
vated ErbB-like receptors are present [40,41].
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Fig. 3. Inhibition of HRG binding to heterodimeric ErbB-IgG fu-
sion proteins by anti-ErbB2 monoclonal antibody, 2C4. Immobilized
ErbB-IgG fusion proteins were immobilized using goat anti-human
Ab (Boehringer Mannheim) as described in Section 2. 125I-HRG
plus varying concentrations of 2C4 were added to wells and assays
were processed as described in Fig. 2. A: ErbB3-containing fusion
proteins. B: ErbB4-containing fusion proteins.
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